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Background: Before 2008, Cancer Care Ontario (CCO) undertook 
provincial cancer control quality-improvement initiatives on a pro-
grammatic basis. CCO has now added Disease Pathway Management 
(DPM) to its quality improvement strategy, with the intent of achiev-
ing high-quality care, processes, and patient experience across the 
patient pathway for specific cancers.
Objectives: The three goals of DPM are: to describe and share evi-
dence-based best practice along the cancer continuum for specific 
cancers; identify quality-improvement priorities for specific cancers 
and catalyze action; monitor performance against best practice for 
specific cancers. The objective of this article is to describe the pro-
cess by which the CCO lung cancer (LC) DPM was initiated and 
some of its early successes.
Methods: In 2009, LC DPM began with a draft LC disease path-
way map and the establishment of five multidisciplinary working 
groups, each focused on a phase of the LC patient journey: preven-
tion, screening, and early detection; diagnosis; treatment; palliative 
care, end-of-life care, and survivorship; and patient experience. The 
working groups held 25 meetings of 2-hour duration and developed 
concepts for 17 quality-improvement projects across the patient jour-
ney. Eight were selected for detailed discussion at a provincial con-
sensus conference, which provided input on priorities for action. A 
report on the priorities for action was prepared and widely circulated, 
and regional roadshows were held in all 14 regions of the province of 
Ontario. Region-specific data on incidence, stage, treatment compli-
ance, and wait times among other issues relevant to LC, were shared 
with the regional care providers at these roadshows. Funding was 
provided by CCO to address opportunities for regional improvement 
based on the data and the priorities identified.
Results: The LC disease pathways were refined through substantial 
multidisciplinary discussion, and the diagnostic pathway was posted 
on CCO’s Web site in February 2012. The treatment pathways for 
small-cell LC and non–small-cell LC were posted in November 
2012. LC Diagnostic Assessment Units/Programs have been initi-
ated in 14 regions, and educational materials on dyspnea manage-
ment, including a patient video, are available on CCO’s Web site. 
An audit has been undertaken to better understand the barriers to the 
uniform uptake of specific evidence-based practices across the prov-
ince, and the results will be reported shortly. The proportion of LC 
patients, whose symptoms are assessed at least once a month, using a 
standardized symptom assessment instrument (Edmonton Symptom 
Assessment System), has improved through the DPM.
Conclusion: Through CCO’s LC DPM initiative, Regional Cancer 
Programs have become aware of their performance on a range of 
LC-specific performance and quality metrics and have been moti-
vated to undertake quality-improvement initiatives. Standardized 
diagnostic and treatment pathways have been developed. Ongoing 
measurement of a broad range of metrics, including stage-specific 
survival, guideline concordance, and measures of the patient experi-
ence will help determine the benefit of this major initiative.
Key Words: Lung cancer, Management, Quality improvement, 
Pathways.
(J Thorac Oncol. 2013;8: 876-882)
Lung cancer (LC), a predominantly smoking-related can-cer, is a growing global health problem because of its high 
mortality rate. In Canada, which has a population of only 33 
million, it was estimated that there would be 26,500 individu-
als diagnosed with LC in 2012, and 20,100 deaths.1 In both 
Canadian men and women, LC is the second-most common 
cancer after cancer of the prostate and breast. In Ontario, the 
poor 5-year survival rate of 16% is attributable to the fact that 
LC typically presents in an advanced stage, with 60% of non–
small-cell and 84% of small-cell LCs diagnosed as either stage 
III or IV.2 The unique stigma associated with LC may also con-
tribute to the poor survival outcomes because patients and their 
families tend to be less aggressive in seeking optimal care.3
Nevertheless, the picture is not entirely negative. In 
Ontario, there has been a 20% reduction in the smoking rate 
of the population from the early 1960s to 2000.4 Clinical 
trials have demonstrated a dramatic improvement in 5-year 
survivorship for some stages of surgically resected LC 
with the use of adjuvant chemotherapy.5 Modest survival 
improvements have been achieved with combined modality 
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therapy for locally advanced cancer, and quality of life and 
overall survival have improved with palliative chemotherapy 
and good supportive care for stage IV LC.6 Advances in 
molecular oncology have identified subpopulations of patients 
who derive greater benefit with targeted therapies.7 Recently, 
evidence has been presented that LC mortality can be reduced 
with low-dose CT screening.8 Clearly, progress has occurred 
and more is imminent, but adoption of new approaches tends 
to be slow and uneven across large jurisdictions.
Undertaking Disease Pathway Management 
for Quality Improvement in Ontario
Cancer Care Ontario (CCO) is the provincial govern-
ment agency with the mandate to improve the quality of can-
cer services and ensure that patients in Ontario receive the 
right care at the right time in the right location by the right 
care provider, at every step of the cancer journey. To improve 
quality in Ontario’s 14 regional cancer programs, CCO has 
used a defined performance improvement cycle on a program-
matic basis, which includes active clinical engagement and 
funding levers supported by an integrated clinical/administra-
tive accountability framework.
In 2008, with the support of senior management and 
the CCO Board of Directors, CCO launched a new approach 
to quality improvement—Disease Pathway Management 
(DPM)—designed to complement the existing specialty pro-
gram-based approach. Besides supporting the mission and 
mandate of CCO, the goal of DPM is to develop, implement, 
and evaluate an integrated series of activities aimed at advanc-
ing system-wide improvements for a specific cancer type 
across the continuum of cancer control. Specifically, DPM 
focuses on ways to improve the quality and processes of care 
and the patient experience for each type of cancer.
Other jurisdictions have implemented disease-manage-
ment strategies for quality improvement, with care pathways 
being the sole driver for quality improvement.9–12 CCO’s DPM 
program is unique in that it incorporates quantitative data from 
the pathways with qualitative inputs from multidisciplinary 
group discussions, to identify opportunities for improvement. 
The LC DPM was launched in 2009. This article describes 
how the LC DPM initiative was organized, the opportunities 
for improvement that were identified, and the early successes 
that have been achieved to date.
LC DPM, Phase 1: Identifying 
Priorities for Action
Clinical leadership for the DPM initiative was sought 
from within the Ontario thoracic oncology community, in 
accordance with CCO’s established approach of seeking clini-
cal engagement in quality-improvement initiatives. Invitations 
were extended to two medical experts, who were the co-leads 
of the existing provincial LC disease site group, which pro-
duces clinical practice guidelines. These individuals had 
established credibility with their peers through their provin-
cial leadership roles and had a network of care providers who 
could be engaged for the work.
The LC DPM co-Chairs invited a broad spectrum of 
multidisciplinary stakeholders from across the province and 
the cancer continuum to participate in the initiative. In total, 
48 individuals agreed to participate, including clinical repre-
sentatives from primary care, public health, occupational med-
icine, oncology, and supportive services, as well as patients 
and caregivers. At an introductory workshop, the participants 
were organized into four working groups to focus on the sepa-
rate phases of the patient’s journey: prevention and screening/
early detection; diagnosis; treatment; palliative care, end-of-
life care, and survivorship. In addition, a patient and family 
advisory group was established. Over the course of 6 months, 
each multidisciplinary working group was asked to use their 
experience and the data provided by CCO to identify gaps in 
service provision and quality-of-care issues, which impacted 
patient satisfaction. The data that CCO was able to provide on 
aspects of LC management, included wait times for treatment, 
concordance of practice with guidelines, LC symptom bur-
den, patient satisfaction, regional LC incidence, and smoking 
rates. The five working groups met for a total of 50 hours, and 
generated 17 priorities for action (Priorities).
In addition to identifying the Priorities, the clinical 
membership of the LC DPM team worked with CCO staff, to 
develop disease pathway maps (pathways) of recommended 
diagnostic procedures and treatment approaches for typical 
small-cell and non–small-cell LC patients. These were based 
to the extent possible on the practice guidelines developed 
through the provincial lung disease site group and CCO’s 
Program in Evidence-based Care. Links to the practice guide-
lines have been embedded in the pathway maps. Wherever evi-
dence was not available, the pathways were informed by expert 
opinion. The pathways have become an important byproduct 
of the DPM work because they are now a valuable resource for 
CCO use in managing the performance of each of the province’s 
regions, planning new quality-improvement activities, promot-
ing best practice, and the use of currently available resources 
(e.g., guidelines, symptom-management aids). Figure 1 depicts 
a portion of the lung diagnosis clinical pathway and the inte-
gration of best practice guidelines into the pathway. The com-
plete pathway can be viewed on the CCO Web site.13
After identification of the Priorities, a provincial sym-
posium was organized to share the Priorities with a larger LC 
community and to solicit feedback on how to move forward. 
Recognizing that it would be impossible to solicit input on 
all 17 Priorities in a single day, the LC DPM leadership team 
further prioritized the Priorities list, and identified eight topics 
to be discussed at the symposium (Table 1).
One hundred fifteen individuals attended the event, 
including frontline clinical experts involved in the diagnosis 
and care of LC patients, health care administrators, 
ministry of health representatives, patients, and caregivers. 
The interactive and multidisciplinary day yielded fruitful 
discussions regarding the relative importance of each priority 
and a set of concrete suggestions on the implementation of the 
eight Priorities.
A key output of this first phase of the LC DPM initia-
tive was the production of a Priorities report, in which each 
of the identified Priorities from the working groups was sum-
marized, along with the recommendations for implementation 
from the provincial symposium.
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LC DPM, Phase 2: Sharing Priorities 
and Promoting Action
The second phase of the LC DPM focused on promoting 
the Priorities agreed on to Ontario’s 14 regional cancer pro-
grams to catalyze action against them. This included a series 
of regional engagement sessions, a provincial pilot project, 
and the provision of provincial funds to each region for the 
purpose of acting on an initiative of high priority in that par-
ticular region.
Regional engagement sessions
To share the Priorities more broadly and to catalyze 
local action, engagement sessions were scheduled in each of 
Ontario’s 14 regional cancer programs. The individuals invited 
to attend these sessions by each regional cancer program 
included local diagnostic imaging experts, thoracic surgeons, 
radiation and medical oncologists, primary-care and palliative 
medicine physicians, nurses, and those involved in smoking 
cessation. There was a deliberate focus on multidisciplinary 
attendance to promote cross-disciplinary discussions on the 
Priorities and potential actions in each region.
Sessions, led by one of the clinical co-Chairs and the 
program manager, included a presentation of the regional 
data covering the cancer control continuum (Table 3). The 
use of data as a conversation starter proved an effective way 
to achieve physician engagement. Although the physicians 
raised issues about the quality of some of the data or the 
time period it covered, the data were, nonetheless, effective 
in sparking discussions. Because each region had some areas 
where they excelled, and some other where there was oppor-
tunity for improvement, it was possible to both celebrate suc-
cesses, and challenge participants to identify strategies for 
further improvements.
Wherever possible, data specific to the Priorities were 
presented. For example, data demonstrating a tight correlation 
between regional smoking rates and LC incidence highlighted 
the need for smoking-cessation programs, particularly in those 
areas of the province with the highest smoking rates. Data on 
the LC symptom burden obtained through a provincial initia-
tive to capture the symptoms of LC patients at regional cancer 
centers, using the Edmonton Symptom Assessment System 
(ESAS), highlighted the need for dyspnea-management pro-
grams (Fig. 2).
When data specific to one of the Priorities were not 
available, related data were used to segue to the priority issue. 
For example, wait-time data for the interval from diagnosis to 
first treatment was used to discuss the patient experience and 
the need to make improvements in the diagnostic phase of the 
LC journey.
Throughout the regional presentations, the LC DPM 
co-Chairs provided anecdotes from their personal experiences 
in managing LC, and the program manager added information 
about current quality-improvement activities in LC or other 
cancers, which were underway within the province to stimulate 
ideas for local action. At the conclusion of each regional 
session, the Priorities report was reviewed and copies were 
FIGURE 1.  Lung Cancer Diagnosis Pathway. CT, computed tomography MRI, magentic resonance imaging, CBC, complete 
blood count; INR, international normalized ratio; PFT, pulmonary function test; PTT, partial thromboplastin time.
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left with the participants to stimulate further discussion at the 
regional level about quality-improvement initiatives.
Initial pilot:– Dyspnea management
In addition to the regional engagement sessions, the LC 
DPM leadership team decided to promote action against the 
Priority of dyspnea management. This Priority was selected 
because more than 60% LC patients in Ontario report some 
level of dyspnea,14 and an evidentiary review demonstrated 
that minimal nursing intervention is effective in improving LC 
patients’ dyspnea, World Health Organization performance 
status, and levels of depression.15
CCO held a funding competition and subsequently 
awarded six cancer centers with funds to develop and imple-
ment a 1-year dyspnea-management program. Participating 
centers were required to create a program that addressed both 
the biomedical and psychosocial needs of dyspneic patients. 
Although sites were free to set up dyspnea-management 
services as considered appropriate, all sites were required 
to collect and report on ESAS scores, quality of life (mea-
sured through the European Organization for Research and 
Treatment of Cancer instrument), and both pre- and post- 
enrollment patient satisfaction to evaluate the effectiveness of 
the various approaches being piloted.
On the basis of the successes achieved in these pilot sites, 
and current literature on dyspnea management, the DPM is in 
the process of developing a recommendations report that will 
promote the implementation of the best dyspnea-management 
practices. After completion of the report, a workshop will 
be held to transfer the knowledge obtained during the pilot 
TABLE 1.  Guidelines Linked to Lung Cancer Pathway Maps
Guideline Title URL
D
ia
gn
os
is
EBS #24-2 Referral of suspected lung cancer by primary care 
practitioners
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=104433
EBS # 7–20 18-Fluorodeoxyglucose positron emission 
tomography in the diagnosis and staging of lung 
cancer: a clinical practice guideline
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34341
EBS # 17-6 Invasive mediastinal staging of non-small cell lung 
cancer
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=83787
T
re
at
m
en
t—
N
S
C
L
C
EBS # 7-1-2 Postoperative adjuvant chemotherapy, with or 
without radiotherapy, in completely resected 
non-small cell lung cancer: a clinical practice 
guideline
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=14162
MCC standards Multidisciplinary cancer conference standards http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=14318
MCC tools Multidisciplinary cancer conference tools http://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=8256
EBS #7-3 Management of unresected stage ill non-small cell lung
cancer: a clinical practice guideline
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=14204
EBS #7–10 First-line systemic chemotherapy
in the treatment of advanced non-small cell lung 
cancer
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=45737
EBS #7–12 Altered fractionation of radical radiation therapy in the
management of unresectable non-small cell lung 
cancer
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=14170
Palliative symptom-
management 
guidelines
Symptom management tools http://www.cancercare.on.ca/cms/one.aspx?portalId=1377&pageId=58189
PG #7-4 Use of preoperative chemotherapy with or without 
postoperative radiotherapy in technically 
resectable stage IIIA non-small cell lung cancer
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34359
EBS #7–19 Second-line or subsequent systemic therapy for 
recurrent or progressive non-small cell lung 
cancer: a clinical practice guideline
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34349
AJCC Staging 7th 
Edition
AJCC lung cancer staging http://www.cancerstaging.org/staging/posters/lung12x15.pdf
T
re
at
m
en
t—
S
C
L
C
PG #7-13-1 The role of combination chemotherapy in the initial 
management of limited-stage small-cell lung cancer
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34347
PG #7-13-2 Prophylactic cranial irradiation in small cell lung 
cancer
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34345
PG #7-13-3 The role of thoracic radiotherapy as an adjunct to 
standard chemotherapy in limited-stage small cell 
lung cancer
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=34339
EBS #7–17 Chemotherapy for relapsed small cell lung cancer: a 
clinical practice guideline
http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=14194
AJCC, American Joint Committee on Cancer; EBS, evidence based summary; MCC, multidisciplinary cancer conference; PG, practice guideline.
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projects and to provide an opportunity to discuss the successes 
and challenges encountered. This workshop will encourage 
further dyspnea-management initiatives, which would 
improve the quality and consistency of care for LC patients 
with dyspnea across Ontario.
Provincial improvement projects
To further support action against the Priorities, CCO 
made one-time funding available to each of the regions to 
undertake sustainable quality-improvement activities against 
locally relevant Priorities for lung and colorectal cancers. 
Funding was allocated to the regions using an existing fund-
ing transfer mechanism, with the amount of funds allocated 
to each region being proportional to the LC burden. Each 
region could use their discretion to decide on the alloca-
tion of the funds against the identified LC Priorities. As a 
condition of the funding, regions were required to submit a 
project proposal to CCO for approval, and once approved, 
regions were required to submit an interim and final report at 
6 and 12 months, respectively. In total, 10 LC projects were 
funded.
LC DPM, Phase 3: –Measuring Results
The third phase of the DPM approach is focused on 
measuring the results of the initiative. This phase of the ini-
tiative is still in progress; however, some early achievements 
have been realized.
The dyspnea-management pilot projects demonstrated 
a statistically significant improvement in patients’ dyspnea as 
measured by ESAS, with 45% of patients with severe dyspnea 
scores reporting a moderate or mild score by their last visit, 
and 32% of patients with an initial moderate dyspnea score 
reporting a mild score by their last visit. Patients also reported 
high levels of satisfaction, feelings of empowerment, and an 
improved ability to continue with their daily activities. This 
pilot also resulted in the creation of new patient materials, 
TABLE 2.  Priorities for Action Discussed at Lung Cancer Symposium
Priority Working Group
Smoking cessation in RCCs Prevention & screening
Occupational and environmental risks at the primary-care level. Promote awareness, connect symptoms with exposure 
and promote swift action
Prevention & screening
Destigmatize lung cancer. Reduce the stigma associated with lung cancer from a patient and health care professional 
perspective
Prevention & screening
Optimize the use of diagnostic imaging in lung cancer. Standardize imaging procedures and implement synoptic 
reporting
Diagnosis
Improve the referral process. Ensure appropriate and efficient referrals both into and within the cancer system Treatment
Manage transitions between care providers. Manage transitions between providers efficiently and effectively along the 
cancer journey
Palliative care, EOL, survivorship 
(cross-journey)
Standardize patient information. Ensure that patients have access to and are provided with the right information at the 
right time across the journey
Patient and family advisory
Educate Healthcare Professionals outside the Cancer System on Lung Cancer. Improve the understanding of lung 
cancer to help leverage care provided by non-oncology health professionals during the journey
Palliative care, EOL, survivorship
EOL, end-of-life care; RCCs, regional cancer centers.
TABLE 3.  Summary of Data Presented at Regional 
Roadshows
Information and Data Presented
Proportion of small-cell lung cancer vs. non–small-cell lung cancer 
diagnosis in Ontario
Age-standardized incidence rates (by region)
Correlation between age-standardized incidence and smoking rates (by 
region)
Proportion of NSCLC patients diagnosed at stage III or IV (by region)
Median wait time from diagnosis to first treatment (by region)
Median wait time from diagnosis to first treatment (by type of treatment)
Proportion of NSCLC patients who did not receive any treatment after 
diagnosis (by region)
Proportion of stage II and IIIA NSCLC resected patients who receive 
adjuvant chemotherapy (by region)
Lifetime radiation use rates for lung cancer (by county)
Proportion of unresected stage IIIA and IIIB NSCLC patients who received 
chemotherapy and radiation (by age bracket)
Proportion of unresected stage IIIA and IIIB NSCLC patients who received 
concurrent chemotherapy and radiation (by region)
Proportion of lung cancer patients screened for symptoms using ESAS (by 
region)
ESAS screening rates over time (region-specific)
Distribution of symptoms for lung cancer patients (as reported by ESAS)
Proportion of lung cancer patients that access the emergency department 3 
months after diagnosis
Proportion of lung cancer patients that access the emergency department 
within 3 months of death
The proportion of lung cancer patients who received chemotherapy in the 
last 2 weeks of life (by region)
Proportion of lung cancer patients who felt their GP knew enough about 
their cancer care
Proportion of lung cancer patients who felt they were informed about their 
follow-up care after treatment
ESAS, Edmonton Symptom Assessment System; GP, general practitioner; NSCLC, 
non–small-cell lung cancer. 
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including a video on how to manage dyspnea, which is posted 
on the CCO Web site.16
Of the 10 regional improvement projects focused on 
LC, four concentrated on smoking cessation, whereas oth-
ers focused on patient education, resource use, and ESAS 
evaluation. Interim reports submitted to CCO show some 
initial successes. One region that proposed to improve their 
multidisciplinary LC case conferences, demonstrated a posi-
tive impact on patient treatment recommendations, whereas 
another region implemented a smoking-cessation program 
that has reached approximately 600 patients in 6 months. At 
the conclusion of these projects, final reports will be sub-
mitted and the learnings from each will be summarized by 
CCO’s provincial office staff and shared with all regional 
cancer programs to facilitate transfer and exchange of 
knowledge.
The LC DPM initiative resulted in the development of 
standardized patient information and provided an update to 
the Understanding Lung Cancer document produced by the 
patient representatives on the provincial LC disease site group. 
Exploration into provincial variance in guideline concordance 
is being examined through a provincial research project on 
guideline adherence led by McMaster University. The report 
produced will increase understanding of how clinical deci-
sions are made and help identify the barriers and enablers to 
implementing practice guideline recommendations. The study 
has noted that the two common barriers were: slow referral 
processes and lack of organizational support for implementa-
tion of guideline recommendations by the administrative lead-
ership. Results from this research will be used to guide future 
activities in knowledge transfer.
Perhaps the most significant accomplishment to date 
has been the creation of pathways depicting the recommended 
and evidence-based management of the diagnostic and treat-
ment phases for small-cell and non–small-cell LC in Ontario. 
After extensive consultation, including presentations at provin-
cial meetings, wide external consultation, and discussion with 
LC experts, the pathways were completed. The LC Diagnosis 
Pathway was the first DPM to be released publicly by CCO on 
its Web site, and the treatment pathways are also available now.17
By working with a team of patients, caregivers, patient 
education specialists, and a graphic designer and writer, DPM 
has begun to develop patient pathway maps. The LC Diagnosis 
Patient Pathway was recently completed and is now avail-
able on the CCO Web site18 and also through the Diagnostic 
Assessment Program Electronic Pathway solution. Work is 
currently underway on additional patient pathway maps. The 
goal of these pathways is to facilitate patient navigation and to 
improve patient and family member access to information and 
coordination of care across the trajectory of care, by provid-
ing a high-level overview flowchart, which would be easy to 
understand.
In addition to the early results achieved by the LC DPM 
initiative, LC became a focus for other program areas within 
CCO. The primary-care program undertook the development 
and publication of a clinical practice guideline targeted at the 
family medicine community, for the early identification and 
referral of patients suspected of having LC.19 It also led to 
the establishment of Diagnostic Assessment Programs for 
LC in every region of the province. The Positron Emission 
Tomography Steering Committee ensured access to positron 
emission tomography for those stages and types of LC where 
the evidence demonstrated clinical utility.20
The provincial symptom-management initiative also 
focused on the LC disease site. Early performance targets 
focused specifically on improving the symptom assessment 
of LC patients through the use of ESAS. Since the incep-
tion of the DPM initiative and start of the LC DPM, ESAS 
use rates by LC patients have gradually increased, allowing 
CCO to gain a better understanding of the symptom burden 
and impact (Fig. 2). The symptom-management guides that 
have been developed by the supportive care program have 
been helpful in supporting quality care for LC patients. The 
dyspnea management guide has been of particular relevance 
to LC.21 Finally, opportunities for reducing the burden of LC 
and improving outcomes for LC patients were spotlighted by 
Ontario’s Cancer Quality Council through its Cancer System 
Quality Index for 2 consecutive years, as a result of CCO’s 
focus on this disease.22
Future steps
As the LC DPM initiative continues to mature, the 
focus will turn to performance measurement and manage-
ment, which is a key pillar of CCO’s approach to quality 
FIGURE 2.  Symptom profile for 
Ontario lung cancer patients using 
the Edmonton Symptom Assessment 
System.
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improvement. The team will work to select and develop new 
metrics related to the Priorities, which will be used to measure 
the performance of the regional cancer programs. Developing 
measures to evaluate regional cancer program concordance 
with the clinical pathways, and their impact on the delivery of 
care, will also be a key focus. Finally, the team will work to 
share the learnings from the various regional quality-improve-
ment projects with all regions of the province, and determine 
how best to report progress on the LC quality initiatives 
through the cancer system quality index.
CONCLUSION
DPM provides a focused and systematic approach by 
which to examine the performance of a cancer system, through 
the lens of the journey that is experienced by a patient with a 
particular type of cancer. CCO has been able to mount this 
large DPM initiative because of the support from the senior 
management team of Cancer Care Ontario, a dedicated DPM 
secretariat, strong clinical leadership, and broad engagement 
of service providers across the spectrum of cancer control. 
The identification of gaps in service or deficiencies in quality 
identified through the focused discussions of the five working 
groups, supported by data, and confirmed through a broad con-
sensus workshop, provided a strong basis for action. Regional 
roadshows helped to accelerate the development of improve-
ment projects and other initiatives to close service gaps. The 
provision of funding from CCO for the regional quality-
improvement projects was critical. The focus on LC through 
the DPM initiative also stimulated other program areas within 
CCO, to direct organizational energy to LC-specific issues. 
As a result of this initiative, there is now a well-established 
mechanism by which CCO can engage other disease-specific 
groups in future DPM initiatives.
The disease-specific focus and multidisciplinary 
engagement of the LC DPM initiative has yielded significant 
early results for Ontario. The LC Diagnostic and Treatment 
Pathway Maps will serve as a one-stop shop for guidance on 
expectations for cancer care delivery, thus helping to ensure 
consistency of care across the regional cancer programs. 
Moving forward, CCO expects to see continued improvement 
in the early detection and care of LC patients and renewed 
efforts in smoking cessation.
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